BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abdelwahab KS, Ahmed Said ZN. Status of hepatitis C virus vaccination: Recent update. World J Gastroenterol 2016; 22(2): 862-873 [PMID: 26811632 DOI: 10.3748/wjg.v22.i2.862] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Kardani K, Bolhassani A, Kardani M, Agi E; Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran, Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran, Iranian Comprehensive Hemophilia Care Center, Tehran, Iran, Iranian Comprehensive Hemophilia Care Center, Tehran, Iran. Correlation of SARS-CoV-2 Infection with Hepatitis and Liver Disorders. JoMMID 2021;9:122-32. [DOI: 10.52547/jommid.9.3.122] [Reference Citation Analysis]
2 Jalilian S, Latifi SM, Makvandi M, Teimoori A, Azaran A, Parsanahad M, Kayedani G. The evaluation of interferon lambda 4 rs368234815 as a predictor factor in treated patients with chronic hepatitis C genotype 1a infection. Indian J Med Microbiol 2017;35:262-8. [PMID: 28681817 DOI: 10.4103/ijmm.IJMM_16_309] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Taherkhani R, Farshadpour F. Global elimination of hepatitis C virus infection: Progresses and the remaining challenges. World J Hepatol 2017; 9(33): 1239-1252 [PMID: 29312527 DOI: 10.4254/wjh.v9.i33.1239] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
4 Zając M, Muszalska I, Sobczak A, Dadej A, Tomczak S, Jelińska A. Hepatitis C - New drugs and treatment prospects. Eur J Med Chem 2019;165:225-49. [PMID: 30685524 DOI: 10.1016/j.ejmech.2019.01.025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
5 Hasanshahi Z, Hashempour A, Ghasabi F, Moayedi J, Musavi Z, Dehghani B, Sharafi H, Joulaei H. First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients. BMC Gastroenterol 2021;21:443. [PMID: 34819046 DOI: 10.1186/s12876-021-01988-y] [Reference Citation Analysis]
6 Dawood RM, Salum GM, Abdelhafez TH, El Shenawy R, Ibrahim NE, El Awady MK. Safety and tolerability of mice to repeated subcutaneous injections of a peptide mix as a potential vaccine against HCV infection. Hum Antibodies 2019;27:105-10. [PMID: 30594921 DOI: 10.3233/HAB-180354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Han J, Zhao D, Li D, Wang X, Jin Z, Zhao K. Polymer-Based Nanomaterials and Applications for Vaccines and Drugs. Polymers (Basel) 2018;10:E31. [PMID: 30966075 DOI: 10.3390/polym10010031] [Cited by in Crossref: 103] [Cited by in F6Publishing: 65] [Article Influence: 25.8] [Reference Citation Analysis]
8 Trucchi C, Orsi A, Alicino C, Sticchi L, Icardi G, Ansaldi F. State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization. J Immunol Res 2016;2016:1412840. [PMID: 27843956 DOI: 10.1155/2016/1412840] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
9 Abd Ellah NH, Tawfeek HM, John J, Hetta HF. Nanomedicine as a future therapeutic approach for Hepatitis C virus. Nanomedicine (Lond) 2019;14:1471-91. [PMID: 31166139 DOI: 10.2217/nnm-2018-0348] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
10 Kardani K, Basimi P, Fekri M, Bolhassani A. Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development. Expert Rev Clin Pharmacol 2020;13:1001-46. [PMID: 32838584 DOI: 10.1080/17512433.2020.1814743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Marín MQ, Pérez P, Gómez CE, Sorzano CÓS, Esteban M, García-Arriaza J. Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression. Viruses 2018;10:E414. [PMID: 30096846 DOI: 10.3390/v10080414] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
12 Razin M, Abdel-Ghaffar AB, Hamdy GM, Abd-Elshafy DN, Kamel S, Bahgat MM, Maghraby AS. TLR3\TLR7 as Differentially Expressed Markers Among Viral, Nonviral, and Autoimmune Diseases in Egyptian Patients. Viral Immunol 2021. [PMID: 34342515 DOI: 10.1089/vim.2021.0006] [Reference Citation Analysis]
13 Lee JC, Lin CK, Tseng CK, Chen YL, Tzeng CC, Tseng CH. Discovery of 3-Amino-2-Hydroxypropoxyisoflavone Derivatives as Potential Anti-HCV Agents. Molecules 2018;23:E2863. [PMID: 30400244 DOI: 10.3390/molecules23112863] [Reference Citation Analysis]